US · COYA
Coya Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Houston, TX 77057
- Website
- coyatherapeutics.com
Price · as of 2024-12-31
$4.17
Market cap 82.41M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $30.48 | +630.94% |
| Intrinsic Value(DCF) | $1.10 | -73.62% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $30.17 | +623.48% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | $4.60 | ||||
| 2023 | $9.39 | ||||
| 2024 | $6.88 | $30.48 | $1.10 | $0.00 | $30.17 |
AI valuation
Our deep-learning model estimates Coya Therapeutics, Inc.'s (COYA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $30.48
- Current price
- $4.17
- AI upside
- +630.94%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.10
-73.62% upside
Graham-Dodd
—
— upside
Graham Formula
$30.17
+623.48% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| COYA | Coya Therapeutics, Inc. | $4.17 | 82.41M | +631% | -74% | — | +623% | -7.05 | 2.65 | 29.50 | -3.87 | -29.29 | 2.65 | -233.86% | -485.35% | -418.70% | -39.57% | -774.97% | -34.76% | 0.00 | — | 11.59 | 10.22 | 2.23 | 2405.00% | -4079.00% | -804.00% | -9.81% | -2.69 | -484.62% | 0.00% | 0.00% | 5.45% | -3.86 | -6.46 | 18.71 | 11.79 |
| CLNN | Clene Inc. | $5.23 | 48.62M | +633% | -65% | — | +3,976% | -0.81 | -3.60 | 93.13 | -1.20 | — | -3.60 | 79.53% | -9676.32% | -11520.47% | -1738.36% | -637.51% | -98.90% | -2.35 | -8.14 | 1.57 | 1.22 | -0.26 | -3987.00% | -4771.00% | -3003.00% | -67.00% | -2.07 | -411.12% | 0.00% | 0.00% | 0.00% | -1.22 | -1.90 | 118.53 | -17.65 |
| CNTX | Context Therapeutics Inc. | $2.25 | 206.73M | — | — | — | — | -1.75 | 0.49 | — | 1.59 | — | 0.49 | 0.00% | — | — | -49.89% | 3929.63% | -46.81% | 0.00 | — | 35.62 | 34.36 | 3.15 | -6933.00% | — | 3927.00% | -62.65% | -5.30 | 3849.40% | 0.00% | 0.00% | 170.46% | 1.58 | 1.62 | — | 8.62 |
| IMMX | Immix Biopharma, Inc. | $8.07 | 270.94M | — | — | — | — | -1.99 | 3.24 | — | -1.17 | — | 3.24 | 0.00% | — | — | -145.76% | 1016.65% | -100.83% | 0.08 | — | 2.33 | 2.26 | 0.74 | -1461.00% | — | 3807.00% | -36.69% | -1.68 | 707.20% | 0.00% | 0.00% | 0.00% | -1.16 | -1.67 | — | -4.58 |
| MGNX | MacroGenics, Inc. | $1.99 | 125.88M | +1,648% | -54% | — | — | -2.12 | 1.22 | 0.96 | 0.38 | -0.35 | 1.22 | 91.71% | -74.54% | -45.14% | -49.85% | 242.04% | -23.91% | 0.32 | -99.17 | 3.92 | 3.71 | 2.53 | 61333.00% | 15937.00% | -987.00% | -50.71% | -1.23 | 157.77% | 0.00% | 0.00% | 55.15% | 0.20 | 0.31 | -0.15 | -5.76 |
| ORMP | Oramed Pharmaceuticals In… | $3.42 | 136.08M | +1,195% | — | — | — | -5.13 | 0.67 | — | 2.94 | — | 0.67 | 0.00% | — | — | -12.29% | -43.99% | -10.14% | 0.00 | -14.98 | 25.19 | 24.97 | 3.63 | -43571.00% | -10000.00% | -2009.00% | -8.62% | -1.48 | -29.02% | 0.00% | 0.00% | 101.31% | 3.42 | 5.19 | — | 5.11 |
| OVID | Ovid Therapeutics Inc. | $1.63 | 116.08M | +1,596% | -87% | — | — | -1.39 | 0.54 | 65.14 | 0.03 | — | 0.54 | 100.00% | -10933.75% | -4670.14% | -33.88% | -444.08% | -22.38% | 0.22 | — | 5.32 | 5.04 | 0.20 | -5000.00% | 4439.00% | 2201.00% | -151.96% | -5.32 | -402.05% | 0.00% | 0.00% | 1.37% | 0.02 | 0.03 | -2.56 | -5.32 |
| PLRX | Pliant Therapeutics, Inc. | $1.30 | 79.88M | +1,747% | — | — | — | -0.47 | 0.32 | — | 0.96 | -1.78 | 0.32 | 0.00% | — | — | -54.09% | 61060.16% | -46.27% | 0.20 | -75.52 | 10.91 | 10.78 | 0.05 | 2618.00% | -10000.00% | 3587.00% | -162.48% | -4.68 | 42607.22% | 0.00% | 0.00% | 0.00% | 0.86 | 1.24 | — | -2.77 |
| STTK | Shattuck Labs, Inc. | $3.92 | 187.78M | +1,035% | -87% | — | — | -0.83 | 0.78 | 10.91 | 0.09 | — | 0.78 | 100.00% | -1408.27% | -1318.13% | -67.23% | -568.84% | -60.18% | 0.04 | — | 8.88 | 8.19 | 0.70 | -2732.00% | 24526.00% | -2580.00% | -97.02% | -6.79 | -427.68% | 0.00% | 0.00% | 0.00% | 0.09 | 0.12 | -1.25 | -4.52 |
| WHWK | Whitehawk Therapeutics In… | $3.51 | 165.42M | +472% | -63% | — | — | -0.90 | 1.09 | 2.21 | -0.17 | — | 1.09 | -108.04% | -259.62% | -245.13% | -80.79% | -3655.27% | -62.83% | 0.02 | -438.04 | 3.59 | 3.11 | 0.43 | -328.00% | 669.00% | -382.00% | -106.81% | -3.49 | -3316.39% | 0.00% | 0.00% | 0.00% | -0.16 | -0.18 | 0.42 | -6.74 |
| ZNTL | Zentalis Pharmaceuticals,… | $2.39 | 172.68M | — | -34% | — | — | -0.78 | 0.38 | 1.92 | 1.07 | — | 0.38 | 100.00% | -283.57% | -245.96% | -42.83% | -4301.81% | -33.43% | 0.13 | — | 7.32 | 7.13 | -0.05 | -4787.00% | — | -1791.00% | -132.25% | -3.24 | -3849.27% | 0.00% | 0.00% | 6.95% | 1.04 | 1.16 | -2.95 | -2.98 |
About Coya Therapeutics, Inc.
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.
- CEO
- Arun Swaminathan
- Employees
- 8
- Beta
- 0.27
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.10 ÷ $4.17) − 1 = -73.62% (DCF, example).